Daniel Malarek: The US FDA has approved Foundation Medicine’s first companion diagnostic indication to support pediatric patients
Daniel Malarek, Chief Executive Officer at Foundation Medicine, shared a post on LinkedIn:
“Excited to share more incredible progress from the Foundation Medicine team. The US FDA has approved our first companion diagnostic indication to support pediatric patients.
Our high-quality tissue-based biomarker test can help healthcare providers connect their pediatric patients and families with a targeted therapy for those with relapsed or refractory pediatric-low grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Our test is the first and only companion diagnostic for this therapy.
Thank you to the cross-functional team at Foundation Medicine for continuing to advance our mission of transforming cancer care. This approval adds to our legacy of developing high-quality diagnostic tests to identify the genomic mutations driving a patient’s tumor and match a patient to the most effective treatment options.
Read more here.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023